Blood Immune Markers Studied in Hodgkin Lymphoma Patients Receiving Pembrolizumab
Studies immune cell changes in blood of adults with relapsed Hodgkin lymphoma treated with pembrolizumab.
Plain-language title generated from the registry record
Registry title: Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's Lymphoma
Key facts
- Where
- Bologna, ItalySee the site
Where in Italy
- IRCCS Azienda Ospedaliero-Universitaria di BolognaBologna, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Trial code
- NCT06733987
- Record updated
- 13 December 2024
- Original description
This is a single-centre, observational, prospective and exploratory study, which involves the use of human tissues from patients affected by Relapsed/Refractory classic Hodgkin Lymphoma treated with pembrolizumab at the Departmental Diagnosis and Therapy program for chronic lymphoproliferative syndromes of the IRCCS AOU of Bologna. Peripheral blood samples will be used for the study and will be taken:Read full original descriptionShow less
Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's Lymphoma
This is a single-centre, observational, prospective and exploratory study, which involves the use of human tissues from patients affected by Relapsed/Refractory classic Hodgkin Lymphoma treated with pembrolizumab at the Departmental Diagnosis and Therapy program for chronic lymphoproliferative syndromes of the IRCCS AOU of Bologna. Peripheral blood samples will be used for the study and will be taken:
* before starting treatment with pembrolizumab. * undergoing therapy with pembrolizumab (cycle 2 (C2), C3, C4, C8, C12).
Inclusion: Patients of both sexes aged ≥ 18 years at enrollment; Patients affected by cHL R/R candidate to receive a treatment with Pembrolizumab; Signature of informed consent.
Exclusion: none.